logo
Intelligence
Tracking
Tools
logo
Intelligence
Tracking
Tools

CureDuchenne Ventures invests in Entos Pharmaceuticals to support the development of a muscle-targeting therapeutic for Duchenne muscular dystrophy (DMD). The funding amount was not disclosed.

May 22, 2025•7 months ago
EdmontonTherapeuticsBiotechnologyHealth Care

Investors

Cure Duchenne Ventures

Description

Entos Pharmaceuticals, an Edmonton-based biotech company, received an investment from CureDuchenne Ventures. The company plans to use the funds to develop a therapeutic aimed at delivering full-length dystrophin. This initiative targets the treatment of Duchenne muscular dystrophy (DMD). Entos utilizes its innovative Fusogenix PLV platform for genetic medicine delivery.

Company Information

Company

Entos Pharmaceuticals

Location

Edmonton, England, United Kingdom

About

Entos Pharmaceuticals is a clinical-stage genetic medicines company focused on developing cures and improving patients' lives using its proprietary Fusogenix™ PLV™ technology. The company aims to address rare genetic disorders through innovative genetic medicine approaches. Since its founding in 2016, Entos has been committed to advancing next-generation genetic medicines.

Related People

3 contacts

Sign in to view contact details

Sign in to view contact details

Sign in to view contact details

Funding Insights

Based on industry data
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers